Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,957 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 2 Intervention Clear all

Conditions: College Student Drinking
Interventions: Personalized Normative Feedback (PNF), Self-Monitoring (SM), Web-BASICS, Health Promotion Consultation, M-Bridge Online Health Coach; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 21 Years
Enrollment: 891 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms, Non-muscle Invasive Bladder Cancer, Bladder Cancer (BC), Transurethral Resection of Bladdertumors, Transurethral Resection of the Bladder, Non-Muscle Invasive Bladder Carcinoma
Interventions: HISA; Device
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Methicillin-resistant Staphylococcus Aureus
Interventions: Chlorhexidine bath and nasal mupirocin; Drug
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 13 Years and older
Enrollment: 74,256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 42
States / cities: Anchorage, Alaska • Thousand Oaks, California • Aurora, Colorado + 32 more

Conditions: Smoking Cessation
Interventions: Headspace, TEDTalk; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pyruvate Kinase Deficiency
Interventions: RP-L301; Biological
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 8 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Melanoma
Interventions: Indocyanine Green (IC-Green), Imaging; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate, Medication Event Monitoring System (MEMS), Adherence counseling; Drug · Device · Behavioral
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 29
States / cities: Homewood, Alabama • Pheonix, Arizona • Carlsbad, California + 26 more

Conditions: Motor Activity, Weight Loss
Interventions: Standard Care, Technology-based Intervention (TECH); Other · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prader Willi Syndrome, Childhood Obesity
Interventions: Active Play at Home; Behavioral
Lead sponsor: California State University, Fullerton; Other
Eligibility: 8 Years to 15 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Fullerton, California • Gainesville, Florida

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 561
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 431 more

Conditions: Aging, Depression, Cognitive Symptom
Interventions: Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation); Behavioral · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Team-Based Quality Improvement Intervention, Opinion Leader Intervention, Team Based Quality Improvement; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: allo-APZ2-EB; Biological
Lead sponsor: RHEACELL GmbH & Co. KG; Industry
Eligibility: 0 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
Interventions: imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis; Drug · Device · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 35 Years and older
Enrollment: 4,446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 24
States / cities: Los Angeles, California • Palm Springs, California • San Francisco, California + 13 more

Conditions: Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Patient Engagement
Interventions: CKD "What You Need To Know" Workbook System, CKD Action Plan, CKD Web-based Resource List, Food Label reading exercise; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 105 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pregnancy Related, Pelvic Floor Disorders, Obstetric; Injury, Patient Empowerment
Interventions: Pelvic wand; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes (T1D)
Interventions: Sleep stability intervention; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer Disease and Related Dementias (ADRD)
Interventions: Passive Digital Marker for screening for ADRD; Other
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older
Enrollment: 5,325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Carcinoma, Hepatocellular
Interventions: Stereotactic Body Radiation; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy, Metabolism
Interventions: Personalized dietary and wellness program; Other
Lead sponsor: Habit, LLC; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Obesity
Interventions: Social Media Treatments; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts

Conditions: Diet, Healthy
Interventions: Active Cooking Classes, Meal Kits, Recipes; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 25 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide; Radiation · Drug · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Adaptive Preventive Intervention for College Alcohol Use

Feasibility of HISA During TURBT for NMIBC

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)

Mindfulness Training for Smoking Cessation

Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency

Nuclear and Near-Infrared (NIR) Imaging in Melanoma

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

Effect of a Technology-Based Intervention on Weight Change Post-Bariatric Surgery

Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Cognitive Enhancement in Depression (The COG-D Study)

A Study of Strategies to Improve Schizophrenia Treatment

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

A Pragmatic Approach to CKD Patient Education

Perineal Massage Using A Pelvic Wand During Pregnancy

Circadian Mechanisms, Glucose, and CV Risks in T1D

Digital Detection of Dementia (D Cubed) Studies: D2

Dose Escalation Study for Primary Hepatocellular Carcinoma

Personalized Dietary Program and Markers of Wellness

Social Media Obesity Treatment for College Students

Cooking as a Health Behavior in College Students

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma